ClinicalTrials.gg
TerminatedNCT00794417Updated Dec 10, 2020Results posted

A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

A Phase 1/2 interventional study of Aflibercept and Pemetrexed in Advanced Carcinoma and Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Terminated at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-10.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals — 2 open to participants now, 11 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Regeneron Pharmaceuticals.

Enrollment
12th of 18
60 · median 86
Started
2008
the only one that year
Phase 1/2
3 of 21
1 open now
Registered
1st of 21
by date

Among the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 1/2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Carcinoma, Non-Small-Cell Lung by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).

Read the detailed description

The study was conducted in two phases. In phase 1, patients with advanced cancer received different doses of aflibercept in combination with approved doses of pemetrexed and cisplatin. The objective of phase 1 was to determine the safest dose of the combined study medications. This dose was administered to patients with previously untreated NSCLC in phase 2. The phase 2 portion of the study determined if the combination is effective in treating NSCLC.

03

Conditions studied

  • Advanced Carcinoma
  • Non-small Cell Lung Cancer

Keywords

  • advanced cancer
  • lung cancer
  • NSCLC
  • Non-small Cell Lung Cancer
  • aflibercept
  • chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmation of cancer by (tissue sample)
  • Phase 1: patients with advanced or disease that have failed conventional therapy
  • Phase 2: patients with previously untreated NSCLC, excluding squamous cell histology and cavitating lesions
  • Age ≥18 years
  • (ECOG) performance status 0-1
  • Adequate renal, liver and bone marrow function.
  • Negative pregnancy test (serum or urine) in females of within 7 days of the initial dose of aflibercept
  • Ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
  • Institutional Review Board (IRB) approved, signed and dated form

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with study medications
  • Untreated, symptomatic, or progressive Central Nervous System cancer and/or spinal cord compression. Patients with treated must have been without symptoms for at least 3 months
  • Surgery up to 4 weeks prior to the initial administration of aflibercept and/or incomplete wound healing
  • Anti-VEGF therapy up to 4 weeks prior to the initial administration of aflibercept (for phase 1 only)
  • Chemotherapy up to 4 weeks prior to the initial administration of aflibercept (for phase 1 only)
  • Other treatment up to 4 weeks prior to the initial administration of aflibercept
  • Any of the following up to 6 months (24 weeks) prior to the initial administration of aflibercept:

    • Severe cardiovascular disease or event
    • Cerebrovascular accident, , or moderate to severe peripheral neuropathy
    • Erosive esophagitis or gastritis, infectious or inflammatory bowel disease, and diverticulitis
    • Deep vein thrombosis, pulmonary embolism, or other clotting event
    • Episode(s)of moderate to severe, continuous bleeding
  • Breast-feeding or pregnancy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin

    Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m\^2 and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.

    Drug: Aflibercept · Drug: Pemetrexed · Drug: Cisplatin

  • Experimental
    Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin

    Participants received intravenous infusion of aflibercept 2 milligrams per kilogram (mg/kg) followed by pemetrexed 500 mg/square meter (m\^2) and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.

    Drug: Aflibercept · Drug: Pemetrexed · Drug: Cisplatin

  • Experimental
    Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin

    Participants received intravenous infusion of aflibercept 4 mg/kg followed by pemetrexed 500 mg/m\^2 and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.

    Drug: Aflibercept · Drug: Pemetrexed · Drug: Cisplatin

  • Experimental
    Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin

    Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m\^2 and then cisplatin 75 mg/m\^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) for 6 cycles.

    Drug: Aflibercept · Drug: Pemetrexed · Drug: Cisplatin

Interventions

  • Administered in combination with the other two interventions via intravenous infusion.

  • Administered in combination with the other two interventions via intravenous infusion.

    Also known as: Alimta

  • Administered in combination with the other two interventions via intravenous infusion.

    Also known as: Platinol

06

What researchers measure

Primary outcomes

  1. Phase 1: Recommended Dose of Aflibercept for Phase 2

    Recommended Dose was defined as the highest combination dose at which fewer than 33 percent (%) of participants experienced dose limiting toxicity during the first cycle of therapy.

    Time frame: Phase 1: Baseline up to 315 Days

Secondary outcomes

  1. Phase 2: Objective Response Rate

    Objective response rate was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) as assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking the Baseline sum LD as reference.

    Time frame: Phase 2: Baseline (Day 421) up to end of study (Day 972)

  2. Phase 2: Progression-free Survival (PFS)

    PFS was defined as the time in days from the date of first study drug administration to the date of first documentation of tumor progression or death from any cause, whichever occurs first, as assessed by the modified RECIST. Median time of PFS was estimated using Kaplan-Meier method.

    Time frame: Phase 2: Baseline (Day 421) up to end of study (Day 972)

  3. Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (for example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) was defined as an adverse event with an onset that occurs after receiving study drug. Any TEAE included participants with both serious and non-serious AEs.

    Time frame: Phase 1: Baseline up to 751 Days; Phase 2: Baseline (Day 421) up to 972 Days

  4. Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Aflibercept

    The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.

    Time frame: Phase 1 and 2: Pre-dose up to Day 22 post-dose

  5. Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Pemetrexed

    The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.

    Time frame: Phase 1 and 2: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)

  6. Phase 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Aflibercept and Pemetrexed

    Cmax is the maximum observed plasma concentration obtained directly from the concentration versus time curve.

    Time frame: Phase 1 and 2: Aflibercept: Pre-dose up to Day 22 post-dose; Pemetrexed: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)

  7. Phase 1 and 2: Total Body Clearance of Aflibercept

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: Phase 1 and 2: Pre-dose up to Day 22 post-dose

  8. Phase 1 and 2: Total Body Clearance of Pemetrexed

    Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

    Time frame: Phase 1 and 2: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)

  9. Phase 1 and 2: Terminal Half-Life (t1/2) of Aflibercept

    Terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.

    Time frame: Phase 1 and 2: Pre-dose up to Day 22 post-dose

  10. Phase 1 and 2: Terminal Half-Life (t1/2) of Pemetrexed

    Terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.

    Time frame: Phase 1 and 2: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)

  11. Phase 1 and 2: Number of Participants With Positive Anti-drug Antibody (ADA) of Aflibercept

    Serum samples were analyzed by a validated electrochemiluminescence immunoassay to detect the presence of ADA.

    Time frame: Phase 1: Baseline up to 315 Days; Phase 2: Baseline (Day 421) up to Day 739

  12. Phase 1 and 2: Number of Participants With All Grade Glucose Abnormalities

    Time frame: Phase 1: Baseline up to 751 Days; Phase 2: Baseline (Day 421) up to 972 Days

  13. Phase 1 and 2: Number of Participants With All Grade Hematology Abnormalities

    Time frame: Phase 1: Baseline up to 751 Days; Phase 2: Baseline (Day 421) up to 972 Days

07

Results

Posted Dec 10, 2020

Participant flow

The study consisted of 2 phases: phase 1 and phase 2. A total of 18 participants were enrolled in phase 1 of the study and 42 participants were enrolled in phase 2 of the study. Participants enrolled in phase 1 were not eligible for enrollment in phase 2.

Phase 1: Baseline (Day 1) up to Day 751
Participant flow — Phase 1: Baseline (Day 1) up to Day 751
MilestonePhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Started4770
Completed1440
Not completed3330
Withdrew: Death0020
Withdrew: Other un-specified3310
Phase 2: Baseline (Day 421) to Day 972
Participant flow — Phase 2: Baseline (Day 421) to Day 972
MilestonePhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Started00042
Completed0007
Not completed00035
Withdrew: Death0007
Withdrew: Physician decision00011
Withdrew: Withdrawal by subject0004
Withdrew: Other unspecified00013

Outcome measures

PrimaryPhase 1: Recommended Dose of Aflibercept for Phase 2

Recommended Dose was defined as the highest combination dose at which fewer than 33 percent (%) of participants experienced dose limiting toxicity during the first cycle of therapy.

Time frame:
Phase 1: Baseline up to 315 Days
Reported as:
Number · mg/kg
Phase 1: Recommended Dose of Aflibercept for Phase 2
mg/kgPhase 1: All Participants
Phase 1: Recommended Dose of Aflibercept for Phase 26
SecondaryPhase 2: Objective Response Rate

Objective response rate was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) as assessed by modified Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking the Baseline sum LD as reference.

Time frame:
Phase 2: Baseline (Day 421) up to end of study (Day 972)
Reported as:
Number · Percentage of Participants
Phase 2: Objective Response Rate
Percentage of ParticipantsPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 2: Objective Response Rate23.8
SecondaryPhase 2: Progression-free Survival (PFS)

PFS was defined as the time in days from the date of first study drug administration to the date of first documentation of tumor progression or death from any cause, whichever occurs first, as assessed by the modified RECIST. Median time of PFS was estimated using Kaplan-Meier method.

Time frame:
Phase 2: Baseline (Day 421) up to end of study (Day 972)
Reported as:
Median · Days
Phase 2: Progression-free Survival (PFS)
DaysPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 2: Progression-free Survival (PFS)149 (130 to 212)
SecondaryPhase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (for example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event (TEAE) was defined as an adverse event with an onset that occurs after receiving study drug. Any TEAE included participants with both serious and non-serious AEs.

Time frame:
Phase 1: Baseline up to 751 Days; Phase 2: Baseline (Day 421) up to 972 Days
Reported as:
Count of participants · Participants
Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)47742
SecondaryPhase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Aflibercept

The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.

Time frame:
Phase 1 and 2: Pre-dose up to Day 22 post-dose
Reported as:
Mean · Day*milligrams per liter (mg/L)
Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Aflibercept
Day*milligrams per liter (mg/L)Phase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Aflibercept201 ± 96.5330 ± 251442 ± 152402 ± 100
SecondaryPhase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Pemetrexed

The AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity.

Time frame:
Phase 1 and 2: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)
Reported as:
Mean · Hour*milligrams per liter (mg/L)
Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Pemetrexed
Hour*milligrams per liter (mg/L)Phase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Pemetrexed151 ± 30.0151 ± 32.5162 ± 12.6148 ± 24.3
SecondaryPhase 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Aflibercept and Pemetrexed

Cmax is the maximum observed plasma concentration obtained directly from the concentration versus time curve.

Time frame:
Phase 1 and 2: Aflibercept: Pre-dose up to Day 22 post-dose; Pemetrexed: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)
Reported as:
Mean · mg/L
Phase 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Aflibercept and Pemetrexed
mg/LPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Aflibercept53.6 ± 7.1468.6 ± 18.7148 ± 108104 ± 26.2
Pemetrexed124 ± 12.6112 ± 34.7113 ± 24.676.8 ± 40.5
SecondaryPhase 1 and 2: Total Body Clearance of Aflibercept

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
Phase 1 and 2: Pre-dose up to Day 22 post-dose
Reported as:
Mean · Liter/Day/kg
Phase 1 and 2: Total Body Clearance of Aflibercept
Liter/Day/kgPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 1 and 2: Total Body Clearance of Aflibercept0.011 ± 0.0040.016 ± 0.0070.016 ± 0.0090.016 ± 0.004
SecondaryPhase 1 and 2: Total Body Clearance of Pemetrexed

Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.

Time frame:
Phase 1 and 2: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)
Reported as:
Mean · Liter/hour/m^2
Phase 1 and 2: Total Body Clearance of Pemetrexed
Liter/hour/m^2Phase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 1 and 2: Total Body Clearance of Pemetrexed3.40 ± 0.593.47 ± 0.843.10 ± 0.223.49 ± 0.76
SecondaryPhase 1 and 2: Terminal Half-Life (t1/2) of Aflibercept

Terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.

Time frame:
Phase 1 and 2: Pre-dose up to Day 22 post-dose
Reported as:
Mean · Days
Phase 1 and 2: Terminal Half-Life (t1/2) of Aflibercept
DaysPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 1 and 2: Terminal Half-Life (t1/2) of Aflibercept3.16 ± 0.5705.53 ± 5.433.72 ± 1.044.62 ± 1.46
SecondaryPhase 1 and 2: Terminal Half-Life (t1/2) of Pemetrexed

Terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination.

Time frame:
Phase 1 and 2: Pre-dose up to Day 1 post-dose, Day 2 post-dose (only in Phase 1)
Reported as:
Mean · Hours
Phase 1 and 2: Terminal Half-Life (t1/2) of Pemetrexed
HoursPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 1 and 2: Terminal Half-Life (t1/2) of Pemetrexed1.47 ± 0.391.63 ± 0.221.73 ± 0.371.48 ± 0.34
SecondaryPhase 1 and 2: Number of Participants With Positive Anti-drug Antibody (ADA) of Aflibercept

Serum samples were analyzed by a validated electrochemiluminescence immunoassay to detect the presence of ADA.

Time frame:
Phase 1: Baseline up to 315 Days; Phase 2: Baseline (Day 421) up to Day 739
Reported as:
Count of participants · Participants
Phase 1 and 2: Number of Participants With Positive Anti-drug Antibody (ADA) of Aflibercept
ParticipantsPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Phase 1 and 2: Number of Participants With Positive Anti-drug Antibody (ADA) of Aflibercept0012
SecondaryPhase 1 and 2: Number of Participants With All Grade Glucose Abnormalities
Time frame:
Phase 1: Baseline up to 751 Days; Phase 2: Baseline (Day 421) up to 972 Days
Reported as:
Number · Participants
Phase 1 and 2: Number of Participants With All Grade Glucose Abnormalities
ParticipantsPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Hyperglycemia (Non-Fasting)46737
Hyperglycemia (Fasting)1366
Hypoglycemia (Non-Fasting)0005
Hypoglycemia (Fasting)0000
SecondaryPhase 1 and 2: Number of Participants With All Grade Hematology Abnormalities
Time frame:
Phase 1: Baseline up to 751 Days; Phase 2: Baseline (Day 421) up to 972 Days
Reported as:
Number · Participants
Phase 1 and 2: Number of Participants With All Grade Hematology Abnormalities
ParticipantsPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
Absolute Neutrophil Count (ANC)24713
Hemoglobin37616
Platelet Count2428

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to 751 Days for Phase 1 and 972 Days for Phase 2 regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin0/4 (0%)1/4 (25%)4/4 (100%)
Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin1/7 (14.3%)5/7 (71.4%)7/7 (100%)
Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin1/7 (14.3%)3/7 (42.9%)7/7 (100%)
Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin5/42 (11.9%)16/42 (38.1%)41/42 (97.6%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders0/42/70/71/42
CHOLECYSTITISHepatobiliary disorders1/40/70/70/42
CHOLANGITISHepatobiliary disorders0/40/71/70/42
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders0/41/70/70/42
FATIGUEGeneral disorders0/41/70/70/42
DISEASE PROGRESSIONGeneral disorders0/40/71/73/42
CHEST PAINGeneral disorders0/40/71/70/42
HYPOTENSIONVascular disorders0/41/71/70/42
GINGIVAL INFECTIONInfections and infestations0/41/70/70/42
ATRIAL FIBRILLATIONCardiac disorders0/41/70/70/42
Most frequent other events
Showing 10 of 178
Most frequent other events
EventPhase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin
NAUSEAGastrointestinal disorders4/45/76/728/42
VOMITINGGastrointestinal disorders4/44/74/710/42
FATIGUEGeneral disorders4/46/76/728/42
FEELING ABNORMALGeneral disorders4/41/70/70/42
DYSGEUSIANervous system disorders4/41/74/715/42
CONSTIPATIONGastrointestinal disorders3/43/76/722/42
HEADACHENervous system disorders3/41/74/713/42
ANOREXIAMetabolism and nutrition disorders3/44/75/713/42
EPISTAXISRespiratory, thoracic and mediastinal disorders2/41/75/711/42
HYPERTENSIONVascular disorders2/43/75/722/42

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Phase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and CisplatinTotal
<=18 years00000
Between 18 and 65 years4152333
>=65 years0621927
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and CisplatinTotal
Female3421928
Male1352332
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: Aflibercept 2 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 4 mg/kg and Pemetrexed and CisplatinPhase 1: Aflibercept 6 mg/kg and Pemetrexed and CisplatinPhase 2: Aflibercept 6 mg/kg and Pemetrexed and CisplatinTotal
American Indian or Alaska Native00000
Asian00044
Native Hawaiian or Other Pacific Islander00000
Black or African American00022
White3773653
More than one race00000
Unknown or Not Reported10001
08

Study locations

15 sites
  • Arizona Cancer Institute, LLC
    Tucson, Arizona 85715, United States
  • University of Arkansas for Medical Science
    Little Rock, Arkansas 72205, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Palm Beach Institute of Hematology and Oncology
    Boynton Beach, Florida 33435, United States
  • Edward Hines Jr. VA Medical Center
    Hines, Illinois 60141, United States
  • Kentucky Cancer Clinic
    Hazard, Kentucky 41701, United States
  • Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231-1000, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • UNM Cancer Clinic
    Albuquerque, New Mexico 87131, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Presbyterian Hospital Center for Cancer Research
    Charlotte, North Carolina 28204, United States
  • Erie Regional Cancer Center
    Erie, Pennsylvania 16505, United States
  • Schiffler Cancer Center - Medical Oncology Division
    Wheeling, West Virginia 26003, United States
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
09

References and documents

Publications

  • Diaz-Padilla I, Siu LL, San Pedro-Salcedo M, Razak AR, Colevas AD, Shepherd FA, Leighl NB, Neal JW, Thibault A, Liu L, Lisano J, Gao B, Lawson EB, Wakelee HA. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Br J Cancer. 2012 Aug 7;107(4):604-11. doi: 10.1038/bjc.2012.319. Epub 2012 Jul 17. PubMed 22805331 ↗
  • Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Riess JW, Kuo CJ, Liu L, Gao B, Dicioccio AT, Adjei AA, Wakelee HA. A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Br J Cancer. 2014 Feb 4;110(3):602-8. doi: 10.1038/bjc.2013.735. Epub 2013 Nov 28. PubMed 24292447 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2008 to primary completion in Jun 2011, 31 months.

Results were first posted in Dec 2020, 9 years 5 months after primary completion. A results delay was requested in Apr 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2008
First posted
Nov 20, 2008
StartActual
Nov 30, 2008
Primary completionActual
Jun 30, 2011
CompletionActual
Jun 30, 2011
Results delay requested
Apr 17, 2011
Results first posted
Dec 10, 2020
Last update
Dec 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00794417
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Nov 20, 2008
Start date
Nov 30, 2008
Primary completion
Jun 30, 2011
Completion
Jun 30, 2011
Results posted
Dec 10, 2020
Last update
Dec 10, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion